Drug Discovery

Regeneron completes acquisition of Sanofi’s stake in Libtayo

Regeneron Pharmaceuticals has completed the purchase of Sanofi's stake in cancer drug Libtayo (cemiplimab).

Mesh Bio, MultiOmic partner to develop chronic metabolic disease medicines

Digital health start-up Mesh Bio has collaborated with drug discovery company MultiOmic Health to use artificial intelligence (AI) for developing precision medicines and diagnostics for chronic metabolic disease.

Generian, Astellas to develop molecules for undruggable therapeutic targets

Generian Pharmaceuticals has signed a collaboration and exclusive license agreement with Astellas Pharma’s wholly owned subsidiary Mitobridge for the research and development of new small molecules for undruggable therapeutic targets.

Palleon, Henlius partner for bifunctional sialidase therapies development

Palleon Pharmaceuticals and Shanghai Henlius Biotech have entered into a strategic collaboration for the development and commercialisation of two bifunctional sialidase therapies.

ImmunoGen, OBT partner to develop new antibody-drug conjugates for cancers

ImmunoGen and Oxford BioTherapeutics (OBT) have entered into a multi-year research collaboration to develop new antibody-drug conjugates (ADCs) to treat cancers.

Olema Oncology, Aurigene partner to develop new therapies for cancer

Olema Pharmaceuticals (Olema Oncology) has announced an exclusive global license agreement with Aurigene Discovery Technologies to discover, develop, and commercialise new cancer therapies.

Upstream Bio raises funds to develop treatments for inflammatory diseases

Biotech company Upstream Bio has raised $200m in Series A financing round to advance development of new therapeutics for allergic and inflammatory diseases.

Sapience raises funding to advance cancer therapy programmes

Sapience Therapeutics has raised $41m in a Series B funding round to advance the pipeline of peptide therapeutics targeting protein-protein interactions.

PharmEnable, Denali Therapeutics partner for neurodegenerative disease drugs

AI drug discovery firm PharmEnable and biopharmaceutical company Denali Therapeutics have entered into a multi-target collaboration to accelerate drug discovery in neurodegenerative diseases.